BR Biopharma (NASDAQ:BRBI – Get Free Report) is one of 1,748 public companies in the “Capital Markets” industry, but how does it weigh in compared to its competitors? We will compare BR Biopharma to similar businesses based on the strength of its valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and profitability.
Profitability
This table compares BR Biopharma and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BR Biopharma | N/A | N/A | N/A |
| BR Biopharma Competitors | 266.99% | 77.99% | 3.52% |
Analyst Recommendations
This is a summary of recent ratings and recommmendations for BR Biopharma and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BR Biopharma | 1 | 0 | 0 | 0 | 1.00 |
| BR Biopharma Competitors | 5371 | 19705 | 21890 | 613 | 2.37 |
Earnings & Valuation
This table compares BR Biopharma and its competitors revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| BR Biopharma | $2.23 billion | $31.36 million | 138.05 |
| BR Biopharma Competitors | $2.36 billion | $396.81 million | 8.87 |
BR Biopharma’s competitors have higher revenue and earnings than BR Biopharma. BR Biopharma is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Dividends
BR Biopharma pays an annual dividend of $0.42 per share and has a dividend yield of 3.8%. BR Biopharma pays out 525.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. As a group, “Capital Markets” companies pay a dividend yield of 3.2% and pay out 30.8% of their earnings in the form of a dividend.
Insider and Institutional Ownership
30.6% of shares of all “Capital Markets” companies are owned by institutional investors. 12.9% of shares of all “Capital Markets” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
BR Biopharma competitors beat BR Biopharma on 12 of the 14 factors compared.
About BR Biopharma
BRBI BR Partners S.A., through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners S.A. is based in S?o Paulo, Brazil.
Receive News & Ratings for BR Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BR Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
